Unlocking the over-the-counter medicinal cannabis opportunity
Wellnex Life CEO George Karafotias and Chief Strategy Officer Zack Bozinovski provide an overview of the over-the-counter medicinal cannabis opportunity in a special investor briefing.
In this session, they also discussed:
- Why over-the-counter medicinal cannabis is seen as one of the biggest opportunities in Australian pharma in recent times
- How Wellnex is positioned to be one of the front runners and market leaders in the space
- Why medicinal cannabis is a game-changer in the treatment of chronic pain, inflammation and sleep deprivation
Recorded on 14 October 2022 at 12:00pm (AEDT)
FEATURED SPEAKERS
George Karafotias
Chief Executive Officer
George has a lengthy track record in listed companies, holding various senior executive roles. He has had success in restructuring and reinventing ASX-listed companies and implementing turnaround strategies, as demonstrated with Wellnex. George further served as a non-executive Director of Perpetual Resources Limited (ASX: PEC) for around a decade and holds a Bachelor of Commerce degree from the University of Adelaide.
Zack Bozinovski
Chief Strategy Officer
Zack is a highly successful and seasoned executive in the Australian retail industry with over 35 years’ experience within FMCG and Pharmaceutical companies in Australia and internationally. Zack has previously held senior positions at Uncle Tobys/Goodman Fielder, PepsiCo and Sigma and successfully developed and established many brands in the Australian retail sector. Zack most recently held the position of Managing Director at Brands Solutions Australia. Zack was also a co-founder of Voost Vitamins, recently sold to Proctor & Gamble.
Chris Kominatos
General Manager – Scientific and Regulatory Affairs
Chris is a leading pharmaceutical product developer for over 20 years having led many commercialisations of pharmaceutical products and obtaining TGA approvals. Chris has consulted and worked with Australia’s major pharmaceutical companies to obtain regulatory approvals and launch unique products under their banners both for branded and private label and for complementary and scheduled therapeutic goods. Chris leads the scientific and regulatory requirement for the business.
